NVO

#6033
Novo-Nordisk A/S
39.34 USD
+3.66%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
39.11
39.36
Rango anual
35.13
81.44
Cambio diario
+3.66%
Variación mensual
+3.61%
Variación en los últimos 6 meses
-30.27%
Cambio anual
-40.08%
Cierres anteriores
37.95
Abrir
39.14
Bid
Ask
Mínimo
39.11
High
39.36
Volumen
3 152
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 20212022202320242025 TTM

Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark.

Noticias